These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 31521196)

  • 1. Prospects for combining immune checkpoint blockade with PARP inhibition.
    Li A; Yi M; Qin S; Chu Q; Luo S; Wu K
    J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
    Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers.
    Shapiro GI; Barry SM
    Cancer Treat Res; 2023; 186():207-221. PubMed ID: 37978138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
    Seyedin SN; Hasibuzzaman MM; Pham V; Petronek MS; Callaghan C; Kalen AL; Mapuskar KA; Mott SL; Spitz DR; Allen BG; Caster JM
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):81-92. PubMed ID: 32036006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?
    Césaire M; Thariat J; Candéias SM; Stefan D; Saintigny Y; Chevalier F
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30487462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
    Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
    Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
    Post CCB; Westermann AM; Bosse T; Creutzberg CL; Kroep JR
    Crit Rev Oncol Hematol; 2020 Aug; 152():102973. PubMed ID: 32497971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.
    Yi XF; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Han CB; Ma JT
    Biomed Pharmacother; 2023 Jul; 163():114770. PubMed ID: 37105074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises.
    Pham MM; Ngoi NYL; Peng G; Tan DSP; Yap TA
    Trends Cancer; 2021 Oct; 7(10):958-970. PubMed ID: 34158277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 16. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
    Criscuolo D; Morra F; Giannella R; Visconti R; Cerrato A; Celetti A
    J Exp Clin Cancer Res; 2019 Feb; 38(1):91. PubMed ID: 30791940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
    Goncalves A; Mezni E; Bertucci F
    Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers.
    Lee EK; Konstantinopoulos PA
    Ther Adv Med Oncol; 2020; 12():1758835920944116. PubMed ID: 32782491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Moutafi M; Economopoulou P; Rimm D; Psyrri A
    Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.